No headlines found.
Addex to Present at the Swiss Biotech Day 2024
Globe Newswire (Fri, 19-Apr 1:00 AM ET)
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 18-Apr 1:00 AM ET)
Globe Newswire (Thu, 11-Apr 1:00 AM ET)
Globe Newswire (Wed, 3-Apr 1:00 AM ET)
Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.
Addex Therapeutics - American Depositary Shares trades on the NASDAQ stock market under the symbol ADXN.
As of April 24, 2024, ADXN stock price declined to $15.55 with 9,800 million shares trading.
ADXN has a beta of -0.37, meaning it tends to be less sensitive to market movements. ADXN has a correlation of 0.00 to the broad based SPY ETF.
ADXN has a market cap of $16.48 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ADXN stock traded as high as $229.60 and as low as $5.00.
ADXN has underperformed the market in the last year with a price return of +3.7% while the SPY ETF gained +24.2%. However, in the short term, ADXN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +113.0% vs +4.6% return in SPY. But in the last 2 weeks, ADXN shares have been beat by the market, returning -44.3% compared to an SPY return of -2.7%.
ADXN support price is $16.76 and resistance is $20.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADXN stock will trade within this expected range on the day.